Evidence map›Paper›PMID 25045817›Full record

ArticleVaccine2014

Development of an HIV vaccine attitudes scale to predict HIV vaccine acceptability among vulnerable populations: L.A. VOICES.

Sung-Jae Lee, Peter A Newman, Naihua Duan, William E Cunningham

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Human vaccines & immunotherapeutics · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Sung-Jae LeeDepartment of Psychiatry and Biobehavioral Sciences, UCLA Semel Institute, Center for Community Health, University of California, 10920 Wilshire Boulevard, Suite 350, Los Angeles, CA 90024-6521, USA. Electronic address: sjlee@mednet.ucla.edu.
Peter A NewmanFactor-Inwentash Faculty of Social Work, University of Toronto, 246 Bloor Street West, Toronto, ON, Canada M5S 1V4. Electronic address: p.newman@utoronto.ca.
Naihua DuanDepartment of Psychiatry, Columbia University Medical Center, Room Old PI R209, Unit/Box: Biostatistics Division, 1051 Riverside Drive, New York, NY 10032, USA. Electronic address: naihua.duan@columbia.edu.
William E CunninghamDepartment of Health Policy and Management, UCLA Fielding School of Public Health; Division of General Internal Medicine & Health Services Research, UCLA David Geffen School of Medicine, University of California, 640 Charles E Young Dr S, Los Angeles, CA 90024, USA. Electronic address: wcunningham@mednet.ucla.edu.
Columbia University Irving Medical Center · USUniversity of California, Los Angeles · USUniversity of Toronto · CA

Funding

UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAPHAEL J LANDOVITZ · 1997 to 2026
$53.5M
The Center for Health Improvement of Minority ElderlyP30AG021684 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CATHERINE A SARKISIAN · 2002 to 2026
$19.7M
TRAINING COREP20MD000182 · NIMHD · CHARLES R. DREW UNIVERSITY OF MED &SCI · PI MILBURN, NORWEETA GERMAINE, SHAPIRO, MARTIN F. · 2002 to 2016
$16.5M
UCLA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR033176 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2011 to 2011
$15.5M
Post-trial HIV Vaccines: Receptivity, Risk &DisparitiesR01MH069087 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CUNNINGHAM, WILLIAM EMERY · 2004 to 2007
$2.0M
Family-Focused HIV Disclosure Intervention in ThailandK01MH085503 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LEE, SUNG-JAE · 2009 to 2013
$755k
CIHR THA-118570NCRR NIH HHS UL1 RR033176NCRR NIH HHS UL 1RR033176NIA NIH HHS P30 AG021684NIA NIH HHS P30-AG021684NIMHD NIH HHS 2P20MD000182NIMHD NIH HHS P20 MD000182NIMH NIH HHS 5K01MH085503NIMH NIH HHS K01 MH085503NIMH NIH HHS MH58107NIMH NIH HHS P30 MH058107NIMH NIH HHS R01 MH069087NIMH NIH HHS R01MH069087
6 · The paper itself

Abstract

backgroundDecade-long delays in successful implementation of Hepatitis B vaccines and ongoing obstacles in HPV vaccine roll-out suggest the importance of an implementation science approach to prepare for the effective translation of future HIV vaccines from clinical trials into routine practice. The objective of this study was to test HIV vaccine attitude items to develop reliable scales and to examine their association with HIV vaccine acceptability.

methodsHIV vaccine attitude items were assessed as part of the L.A. VOICES survey, a large-scale study conducted among underserved residents of Los Angeles, to identify factors that may influence HIV vaccine acceptability. Participants (n=1225) were randomly selected from public STD clinics, needle exchange sites and Latino community clinics using three-stage, venue-based time space sampling.

resultsExploratory factor analysis across 20 items revealed four distinct factors - mistrust, HIV vaccine social concerns, risk compensation, and altruistic vaccination - with acceptable reliability coefficients for each subscale (Cronbach's α range 0.61-0.84). We found no significant differences in reliability by gender or by vaccine acceptability. Risk compensation (odds ratio (OR)=1.49; 95% CI=[1.18, 1.89]; p=0.001) and altruistic vaccination (OR=1.40; 95% CI=[1.14, 1.71]; p=0.001) were significantly and positively associated with HIV vaccine acceptability.

conclusionsWe identified four HIV vaccine attitude scales with sound internal reliability parameters. In the aftermath of the first candidate vaccine to demonstrate efficacy against HIV infection, these scales may be helpful in bridging expectable research-to-practice gaps in future HIV vaccine dissemination among populations at risk. As HIV vaccine trials progress in the United States and globally, these measures also may be useful as a tool to assess and facilitate effective responses to community concerns about HIV vaccine trials and to target interventions to support recruitment and mitigate risk compensation.

Indexed as

Health Knowledge, Attitudes, PracticeAdultAIDS VaccinesAltruismFemaleHIV InfectionsHumansLos AngelesMalePatient Acceptance of Health CareTrustVaccinationVulnerable PopulationsAIDS VaccinesAcceptability of healthcareAIDS vaccineAltruismAttitudesRisk compensationScale development

Identifiers

PMID25045817
PMCPMC4137321
OpenAlexW2164694165

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.